查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1530824

2030 年疫苗市场预测：按疫苗类型、疾病类型、给药途径、年龄层、最终用户和地区进行全球分析

Vaccines Market Forecasts to 2030 - Global Analysis By Vaccine Type, Disease Type, Route of Administration, Age Group, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2024年全球疫苗市场规模为802.4亿美元，预计2030年将达到973.8亿美元，预测期内复合年增长率为6.2%。

疫苗是生物製药，旨在提供针对特定疾病的免疫力。疫苗含有病原体的弱化或惰性部分，例如蛋白质或遗传物质，以刺激免疫系统识别和对抗病原体。透过触发免疫反应，疫苗可以帮助发育记忆细胞，如果将来接触到病原体，这些细胞可以识别并对抗病原体。这种积极主动的方法有助于预防感染疾病及其併发症，为个人和公共卫生做出贡献。

据联合国卫生机构称，截至 2021 年 9 月，只有 3% 的人至少接种了一剂 COVID-19 疫苗，而高所得国家的比例为 60.18%。

感染疾病增加

随着新发和重新出现的感染疾病感染疾病更加普遍，各国政府和医疗机构正在优先考虑疫苗接种，以保护公众健康并减轻疫情爆发。这种不断增长的需求将推动对疫苗研究、开发和生产的投资。此外，随着疾病爆发，公众意识和紧迫感增强，推动疫苗接种率提高并扩大市场机会。因此，製药公司和研究机构热衷于创新和扩展疫苗解决方案，进一步推动市场成长。

副作用和安全问题

疫苗的不良反应和安全问题源自于个别反应、潜在副作用或罕见併发症。这些问题可能是由疫苗成分、生产过程或潜在的健康状况引起的。这种担忧可能会导致公众怀疑并减少疫苗的使用。负面新闻报导和错误讯息可能会进一步加剧恐惧并影响整体疫苗接种率。信任和需求的下降可能会阻碍市场成长。

增加政府措施和资金

各国政府已拨出大量资金支持疫苗研发，促进创新疫苗的开发和对新兴疾病的快速反应。公共资金也有助于降低疫苗生产成本，并使疫苗更容易获得，特别是在服务不足的地区。此外，政府主导的免疫计划提高了疫苗接种率，改善了公共卫生，并推动了市场需求。这些努力将加强疫苗供应链，促进全球卫生安全，进而推动整体市场成长。

开发和製造成本高

开发和生产疫苗的高成本是由于广泛的研究、临床试验和严格的监管要求所造成的。製造需要复杂的製程、品管和专用设备，这进一步增加了成本。因此，高成本可能会限制疫苗的供应、阻碍广泛的免疫接种以及限制对新疫苗开发和创新的投资，从而减缓市场成长。

COVID-19 的影响

COVID-19大流行加速了疫苗的开发和生产，大大提振了疫苗市场，凸显了快速反应在公共卫生中的关键作用。这场危机引发了前所未有的全球合作和资金筹措，导致了 COVID-19 疫苗的快速生产和分配。这段经历增加了人们对疫苗研究和基础设施的兴趣和投资。然而，它也暴露了疫苗分配不公平和公众犹豫不决等挑战。整体而言，疫情凸显了疫苗的重要性，刺激了产业进步，并影响了未来的市场动态。

预计儿科领域在预测期内将是最大的。

预计儿科业务将出现良好成长。儿科疫苗是专为儿童设计的免疫接种，旨在预防常见和严重的疾病。这些疫苗对于预防麻疹、德国麻疹、德国麻疹和百日咳等疾病至关重要。早期接种疫苗可以帮助儿童在接触这些病原体之前建立对这些病原体的免疫力。免疫接种计划经过精心设计，以确保及时预防，有助于整体公共卫生并减少疾病发病率。

研究机构领域预计在预测期内复合年增长率最高

预计研究机构部门在预测期内将出现最高的复合年增长率。研究实验室使用疫苗来提高对疫苗的科学认识并开发新的免疫技术。研究机构正在对疫苗功效、安全性和创新管理方法进行研究。研究机构正在进行疫苗功效、安全性和创新递送方法的研究，研究新型疫苗平台并探索疾病预防的新目标。研究主导的疫苗开发旨在解决新兴和现有的疾病、改善公共卫生结果并推动医学发展。

比最大的地区

由于医疗保健投资增加、疾病发病率上升和免疫计划扩大，亚太疫苗市场正在经历快速成长。由于人口密度高和新出现疾病的威胁，各国政府正在优先考虑疫苗的可用性和可负担性。疫苗技术的创新和强有力的公共卫生措施正在进一步刺激市场扩张。该地区已成为疫苗开发和分配的关键地区，反映出不断增长的医疗保健需求。

复合年增长率最高的地区：

由于先进的医疗基础设施、高疫苗接种率以及对研发的大量投资，北美疫苗市场仍然强劲。该地区受益于政府的大力支持，包括资金和公共卫生倡议，以及公众对疫苗益处的高度认识。持续的技术创新和新疫苗的快速开发也正在推动市场。总体而言，北美持续引领全球疫苗市场。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球疫苗市场：依疫苗类型

  • 灭活疫苗
  • 减毒活疫苗
  • 结合疫苗
  • mRNA（信使核糖核酸）疫苗
  • DNA（去氧核糖核酸）疫苗
  • 类毒素疫苗
  • 其他疫苗类型

第六章全球疫苗市场：依疾病类型

  • 感染疾病
  • 癌症疫苗
  • 自体免疫疾病
  • 旅行疫苗
  • 其他疾病类型

第七章 全球疫苗市场：依给药途径

  • 注射
  • 口服
  • 鼻腔
  • 经皮的

第八章全球疫苗市场：依年龄组别

  • 小儿科
  • 成人
  • 老年病

第九章 全球疫苗市场：依最终用户分类

  • 医院
  • 药局
  • 公共卫生机构
  • 研究所
  • 其他最终用户

第十章全球疫苗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 公司概况

  • Pfizer Inc.
  • Moderna Inc.
  • Johnson & Johnson
  • Sanofi Pasteur
  • GlaxoSmithKline（GSK）
  • AstraZeneca
  • Novartis AG
  • Merck & Co., Inc.
  • Bavarian Nordic
  • BioNTech SE
  • Serum Institute of India
  • CureVac NV
  • Abbott Laboratories
  • Clover Biopharmaceuticals
  • Inovio Pharmaceuticals
  • Indian Immunologicals Limited（IIL）
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Sinovac Biotech
Product Code: SMRC26936

According to Stratistics MRC, the Global Vaccines Market is accounted for $80.24 billion in 2024 and is expected to reach $97.38 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Vaccines are biological preparations designed to provide immunity against specific diseases. They contain weakened or inactive parts of a pathogen, such as proteins or genetic material, which stimulate the immune system to recognize and fight the pathogen. By triggering an immune response, vaccines help the body develop memory cells that can recognize and combat the pathogen if exposed in the future. This proactive approach helps prevent infections and their potential complications, contributing to individual and public health.

According to the United Nations Health Agency, as of September 2021, only 3% of people had been vaccinated with at least one dose of the covid -19 vaccine, compared to 60.18% in high-income countries.

Market Dynamics:

Driver:

Rising incidence of infectious diseases

As new and re-emerging diseases spread, both governments and healthcare organizations prioritize vaccination to protect public health and mitigate outbreaks. This heightened need drives investments in vaccine research, development, and production. Additionally, increased disease prevalence raises public awareness and urgency, encouraging higher vaccination rates and expanding market opportunities. Consequently, pharmaceutical companies and research institutions are motivated to innovate and scale up vaccine solutions, further fueling market growth.

Restraint:

Adverse reactions and safety concerns

Adverse reactions and safety concerns in vaccines arise from individual responses, potential side effects, or rare complications. These issues can stem from vaccine components, manufacturing processes, or underlying health conditions. Such concerns may lead to public skepticism and decreased vaccine uptake. Negative reports and misinformation can further amplify fears, impacting overall vaccination rates. This reduced trust and lower demand can hamper market growth.

Opportunity:

Mounting government initiatives and funding

Governments allocate substantial resources to support vaccine R&D, facilitating the creation of innovative vaccines and faster response to emerging diseases. Public funding also helps reduce the cost of vaccine production and makes vaccines more accessible, particularly in underserved regions. Additionally, government-led immunization programs increase vaccination rates, boost public health, and drive market demand. These efforts collectively strengthen the vaccine supply chain and promote global health security, fostering overall market growth.

Threat:

High development and production costs

High development and production costs in vaccines arise from extensive research, clinical trials, and stringent regulatory requirements. Manufacturing involves complex processes, quality control, and specialized equipment, further increasing expenses. Consequently, high costs can slow market growth by restricting vaccine availability, impeding widespread immunization efforts, and limiting investments in new vaccine development and innovation.

Covid-19 Impact

The covid-19 pandemic significantly propelled the vaccines market by accelerating vaccine development and production, highlighting the critical role of rapid response in public health. The crisis led to unprecedented global collaboration and funding, resulting in the swift creation and distribution of covid-19 vaccines. This experience boosted interest and investment in vaccine research and infrastructure. However, it also exposed challenges such as vaccine distribution inequities and public hesitancy. Overall, the pandemic underscored the importance of vaccines and spurred advancements in the industry, influencing future market dynamics.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to have a lucrative growth. Pediatric vaccines are immunizations specifically designed for children to protect against common and serious diseases. These vaccines are crucial for preventing illnesses such as measles, mumps, rubella, and whooping cough. Early vaccination helps establish immunity before children are exposed to these pathogens. Immunization schedules are carefully designed to ensure timely protection, contributing to overall public health and reducing disease outbreaks.

The research institutions segment is expected to have the highest CAGR during the forecast period

The research institutions segment is anticipated to witness the highest CAGR growth during the forecast period. In research institutions, vaccines are used to advance scientific understanding and develop new immunization technologies. These institutions conduct studies on vaccine efficacy, safety, and innovative delivery methods. They explore novel vaccine platforms, and investigate new targets for disease prevention. Research-driven vaccine development aims to address emerging and existing diseases, improving public health outcomes and advancing medical science.

Region with largest share:

The vaccines market in the Asia-Pacific region is experiencing rapid growth due to increasing healthcare investments, rising disease incidence, and expanding immunization programs. Governments are prioritizing vaccine accessibility and affordability, driven by high population density and emerging disease threats. Innovations in vaccine technology and robust public health initiatives further stimulate market expansion. The region remains a key area for vaccine development and distribution, reflecting its growing healthcare needs.

Region with highest CAGR:

The vaccines market in North America is robust, driven by advanced healthcare infrastructure, high vaccination rates, and significant investments in research and development. The region benefits from strong government support, including funding and public health initiatives, as well as a high level of public awareness about vaccine benefits. The market is also fuelled by ongoing innovation and the rapid development of new vaccines. Overall, North America remains a leading player in the global vaccine market.

Key players in the market

Some of the key players profiled in the Vaccines Market include Pfizer Inc., Moderna Inc., Johnson & Johnson, Sanofi Pasteur, GlaxoSmithKline (GSK), AstraZeneca, Novartis AG, Merck & Co., Inc., Bavarian Nordic, BioNTech SE, Serum Institute of India, CureVac N.V., Abbott Laboratories, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Indian Immunologicals Limited (IIL), Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company and Sinovac Biotech.

Key Developments:

In January 2024, Indian Immunologicals Ltd (IIL), a wholly-owned subsidiary of National Dairy Development Board (NDDB), launched India's 'first' indigenously developed Hepatitis A vaccine. Havisure is expected to play a key role to protect against the Hepatitis A virus, which primarily affects the liver. The vaccine is effective in preventing the disease and is recommended for children in routine immunisation.

In November 2022, Pfizer Inc. and BioNTech SE have advanced a promising vaccine candidate into clinical trials. Their new mRNA-based combination vaccine aims to tackle two significant respiratory illnesses: influenza and COVID-19. This vaccine, currently in Phase 1 trials, represents a notable step forward in public health innovation.

Vaccine Types Covered:

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Conjugate Vaccines
  • mRNA (messenger Ribonucleic Acid) Vaccines
  • DNA (Deoxyribonucleic Acid) Vaccines
  • Toxoid Vaccines
  • Other Vaccine Types

Disease Types Covered:

  • Infectious Diseases
  • Cancer Vaccines
  • Autoimmune Diseases
  • Travel-Related Vaccines
  • Other Disease Types

Route of Administrations Covered:

  • Injectable
  • Oral
  • Nasal
  • Transdermal

Age Groups Covered:

  • Pediatric
  • Adult
  • Geriatric

End Users Covered:

  • Hospitals
  • Pharmacies
  • Public Health Organizations
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaccines Market, By Vaccine Type

  • 5.1 Introduction
  • 5.2 Inactivated Vaccines
  • 5.3 Live Attenuated Vaccines
  • 5.4 Conjugate Vaccines
  • 5.5 mRNA (messenger Ribonucleic Acid) Vaccines
  • 5.6 DNA (Deoxyribonucleic Acid) Vaccines
  • 5.7 Toxoid Vaccines
  • 5.8 Other Vaccine Types

6 Global Vaccines Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Infectious Diseases
  • 6.3 Cancer Vaccines
  • 6.4 Autoimmune Diseases
  • 6.5 Travel-Related Vaccines
  • 6.6 Other Disease Types

7 Global Vaccines Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Injectable
  • 7.3 Oral
  • 7.4 Nasal
  • 7.5 Transdermal

8 Global Vaccines Market, By Age Group

  • 8.1 Introduction
  • 8.2 Pediatric
  • 8.3 Adult
  • 8.4 Geriatric

9 Global Vaccines Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmacies
  • 9.4 Public Health Organizations
  • 9.5 Research Institutions
  • 9.6 Other End Users

10 Global Vaccines Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer Inc.
  • 12.2 Moderna Inc.
  • 12.3 Johnson & Johnson
  • 12.4 Sanofi Pasteur
  • 12.5 GlaxoSmithKline (GSK)
  • 12.6 AstraZeneca
  • 12.7 Novartis AG
  • 12.8 Merck & Co., Inc.
  • 12.9 Bavarian Nordic
  • 12.10 BioNTech SE
  • 12.11 Serum Institute of India
  • 12.12 CureVac N.V.
  • 12.13 Abbott Laboratories
  • 12.14 Clover Biopharmaceuticals
  • 12.15 Inovio Pharmaceuticals
  • 12.16 Indian Immunologicals Limited (IIL)
  • 12.17 Bayer AG
  • 12.18 Takeda Pharmaceutical Company Limited
  • 12.19 Eli Lilly and Company
  • 12.20 Sinovac Biotech

List of Tables

  • Table 1 Global Vaccines Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Vaccines Market Outlook, By Vaccine Type (2022-2030) ($MN)
  • Table 3 Global Vaccines Market Outlook, By Inactivated Vaccines (2022-2030) ($MN)
  • Table 4 Global Vaccines Market Outlook, By Live Attenuated Vaccines (2022-2030) ($MN)
  • Table 5 Global Vaccines Market Outlook, By Conjugate Vaccines (2022-2030) ($MN)
  • Table 6 Global Vaccines Market Outlook, By mRNA (messenger Ribonucleic Acid) Vaccines (2022-2030) ($MN)
  • Table 7 Global Vaccines Market Outlook, By DNA (Deoxyribonucleic Acid) Vaccines (2022-2030) ($MN)
  • Table 8 Global Vaccines Market Outlook, By Toxoid Vaccines (2022-2030) ($MN)
  • Table 9 Global Vaccines Market Outlook, By Other Vaccine Types (2022-2030) ($MN)
  • Table 10 Global Vaccines Market Outlook, By Disease Type (2022-2030) ($MN)
  • Table 11 Global Vaccines Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 12 Global Vaccines Market Outlook, By Cancer Vaccines (2022-2030) ($MN)
  • Table 13 Global Vaccines Market Outlook, By Autoimmune Diseases (2022-2030) ($MN)
  • Table 14 Global Vaccines Market Outlook, By Travel-Related Vaccines (2022-2030) ($MN)
  • Table 15 Global Vaccines Market Outlook, By Other Disease Types (2022-2030) ($MN)
  • Table 16 Global Vaccines Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 17 Global Vaccines Market Outlook, By Injectable (2022-2030) ($MN)
  • Table 18 Global Vaccines Market Outlook, By Oral (2022-2030) ($MN)
  • Table 19 Global Vaccines Market Outlook, By Nasal (2022-2030) ($MN)
  • Table 20 Global Vaccines Market Outlook, By Transdermal (2022-2030) ($MN)
  • Table 21 Global Vaccines Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 22 Global Vaccines Market Outlook, By Pediatric (2022-2030) ($MN)
  • Table 23 Global Vaccines Market Outlook, By Adult (2022-2030) ($MN)
  • Table 24 Global Vaccines Market Outlook, By Geriatric (2022-2030) ($MN)
  • Table 25 Global Vaccines Market Outlook, By End User (2022-2030) ($MN)
  • Table 26 Global Vaccines Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 27 Global Vaccines Market Outlook, By Pharmacies (2022-2030) ($MN)
  • Table 28 Global Vaccines Market Outlook, By Public Health Organizations (2022-2030) ($MN)
  • Table 29 Global Vaccines Market Outlook, By Research Institutions (2022-2030) ($MN)
  • Table 30 Global Vaccines Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.